CD64 enables TCR-dependent, MHC-independent CTL cytotoxicity of AML cells

K Kapil Saxena (Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center) S Shao-Hsi Hung (Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center) E Esther Ryu (Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center) Y Yulun Chiu (Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center) C Casey Bermack (Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center) K Ke Pan (Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center) C Chunhua Shi (Oncology Research for Biologics and Immunotherapy Translation, The University of Texas MD Anderson Cancer Center) P Priscilla Ortiz (Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center) S Shailbala Singh (Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center) M Marina Y. Konopleva (Department of Leukemia, The University of Texas MD Anderson Cancer Center) C Cassian Yee

Abstract

CD8+ T cell–mediated cytotoxicity classically occurs through engagement of an alpha-beta T cell receptor (TCRαβ) with a peptide–class I major histocompatibility complex (pMHC). However, it is also known that cytotoxic CD8+ T lymphocytes (CTLs) can kill tumor cells in a pMHC-independent manner. The relative physiologic contribution and biological significance of pMHC-independent CTL killing remain unclear, and a receptor shared between CTLs and natural killer (NK) cells is generally invoked as the mechanism by which this occurs. In this study, we used acute myeloid leukemia (AML) as a model to examine mechanisms of pMHC-independent cytotoxicity and found a paradoxical TCR-dependent, MHC-independent mechanism that requires CD64. Utilizing knockouts of potential AML ligands and CTL receptors, we demonstrate that pMHC-independent cytotoxicity is a potent mechanism of CTL-mediating killing of AML cells and is largely restricted to CD64-expressing cells through an IFNγ-regulated process. Notably, we found that pMHC-independent CTL killing is not due to activation of commonly implicated NK activating receptors but rather requires an activated TCRαβ/CD3 complex. Thus, we identify a CD64-dependent, pMHC-independent, TCR-dependent mode of CTL cytotoxicity that appears highly enriched for in AML.

Article Details

Volume / Issue Vol. 123, Issue 29
Published July 21, 2026
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (11)

K

Kapil Saxena

Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

S

Shao-Hsi Hung

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center

E

Esther Ryu

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center

Y

Yulun Chiu

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center

C

Casey Bermack

Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

K

Ke Pan

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center

C

Chunhua Shi

Oncology Research for Biologics and Immunotherapy Translation, The University of Texas MD Anderson Cancer Center

P

Priscilla Ortiz

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center

S

Shailbala Singh

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center

M

Marina Y. Konopleva

Department of Leukemia, The University of Texas MD Anderson Cancer Center

C

Cassian Yee